Free Trial

Soleno Therapeutics (SLNO) Competitors

Soleno Therapeutics logo
$65.94 -1.73 (-2.55%)
As of 01:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SLNO vs. FEMY, IMVT, SOLV, PEN, STVN, IRTC, BLCO, GKOS, TMDX, and NVST

Should you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Femasys (FEMY), Immunovant (IMVT), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), Glaukos (GKOS), TransMedics Group (TMDX), and Envista (NVST). These companies are all part of the "medical" sector.

Soleno Therapeutics vs. Its Competitors

Femasys (NASDAQ:FEMY) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

In the previous week, Soleno Therapeutics had 11 more articles in the media than Femasys. MarketBeat recorded 13 mentions for Soleno Therapeutics and 2 mentions for Femasys. Femasys' average media sentiment score of 0.64 beat Soleno Therapeutics' score of 0.36 indicating that Femasys is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Femasys
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Soleno Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Femasys currently has a consensus price target of $7.33, indicating a potential upside of 853.62%. Soleno Therapeutics has a consensus price target of $115.92, indicating a potential upside of 75.78%. Given Femasys' higher possible upside, equities analysts plainly believe Femasys is more favorable than Soleno Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Femasys
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Soleno Therapeutics
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.93

Femasys has a beta of -2.64, indicating that its share price is 364% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.75, indicating that its share price is 375% less volatile than the S&P 500.

Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,113.72%. Soleno Therapeutics' return on equity of -73.74% beat Femasys' return on equity.

Company Net Margins Return on Equity Return on Assets
Femasys-1,113.72% -713.74% -152.60%
Soleno Therapeutics N/A -73.74%-56.67%

Femasys has higher earnings, but lower revenue than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Femasys$1.63M15.37-$18.82M-$0.86-0.89
Soleno Therapeutics$32.66M107.32-$175.85M-$4.14-15.93

65.3% of Femasys shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 11.5% of Femasys shares are held by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Soleno Therapeutics beats Femasys on 10 of the 17 factors compared between the two stocks.

Get Soleno Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLNO vs. The Competition

MetricSoleno TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.50B$3.02B$6.15B$10.48B
Dividend YieldN/A57.77%5.73%4.78%
P/E Ratio-15.9322.9884.9827.27
Price / Sales107.32625.64574.66178.17
Price / CashN/A172.6337.3961.86
Price / Book11.615.4612.456.71
Net Income-$175.85M$33.06M$3.32B$276.79M
7 Day Performance0.59%-0.96%0.28%-0.77%
1 Month Performance32.66%13.17%10.12%6.38%
1 Year Performance21.00%-2.14%72.36%37.91%

Soleno Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLNO
Soleno Therapeutics
4.394 of 5 stars
$65.95
-2.5%
$115.92
+75.8%
+25.0%$3.50B$32.66M-15.9330
FEMY
Femasys
2.8645 of 5 stars
$0.53
-13.0%
$7.33
+1,276.9%
-52.9%$19.95M$1.63M-0.6230
IMVT
Immunovant
2.1384 of 5 stars
$17.35
+1.9%
$30.38
+75.1%
-37.2%$2.97BN/A-6.09120Analyst Forecast
SOLV
Solventum
2.8956 of 5 stars
$70.89
+0.5%
$84.89
+19.8%
+2.7%$12.23B$8.25B32.8222,000
PEN
Penumbra
4.5115 of 5 stars
$253.02
-2.9%
$303.44
+19.9%
+22.3%$10.16B$1.19B67.294,500Analyst Forecast
Analyst Revision
STVN
Stevanato Group
1.5009 of 5 stars
€23.33
-2.2%
N/A+29.8%€7.07B€1.19B43.205,521
IRTC
iRhythm Technologies
1.4907 of 5 stars
$177.37
+0.7%
$180.23
+1.6%
+192.2%$5.66B$591.84M-60.542,000Analyst Forecast
BLCO
Bausch + Lomb
1.6205 of 5 stars
$14.87
+3.8%
$15.70
+5.6%
-27.7%$5.07B$4.79B-19.0613,500
GKOS
Glaukos
4.342 of 5 stars
$83.11
+0.7%
$116.92
+40.7%
-33.1%$4.73B$383.48M-50.37780Analyst Forecast
TMDX
TransMedics Group
3.1642 of 5 stars
$111.71
+4.1%
$127.18
+13.8%
-14.6%$3.66B$441.54M57.88210Analyst Forecast
NVST
Envista
4.0665 of 5 stars
$19.23
+0.9%
$21.08
+9.6%
+10.6%$3.17B$2.51B60.1012,300News Coverage
Analyst Revision

Related Companies and Tools


This page (NASDAQ:SLNO) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners